Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. ADBE
6. CHWY
7. NAVN
8. NVDA
9. CRWV
10. CME

Go back to Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Nurix (NRIX) PT Lowered to $28 at Needham

January 29, 2025 7:59 AM EST

Needham analyst Gil Blum lowered the price target on Nurix (NASDAQ: NRIX) to $28.00 (from $29.00) while maintaining a Buy rating.

The analyst comments "Financials and Model Updates. In 2024, Nurix received ~$13M in collaboration revenue from its partners including a $5M milestone... More